BioSpace News Archive

InfuSystem Holdings, Inc. announced that Richard DiIorio, Chief Executive Officer, Barry Steele, Chief Financial Officer, and Carrie Lachance, President and Chief Operating Officer will participate in Lake Street Capital Markets’ 7th Annual Best Ideas Growth Conference on Thursday, September 14, 2023.

Merck announced that Caroline Litchfield, executive vice president and chief financial officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, Sept. 11, 2023, at 2:15 p.m. EDT.

Asensus Surgical, Inc. announced that Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the H.C. Wainwright 25th Annual Global Investment Conference.

AC Immune SA (NASDAQ: ACIU) today announced that the Company will present a corporate overview and participate in one-on-one investor meetings during the H.C. Wainwright 25th Annual Global Investment Conference, taking place virtually and in-person at the Lotte New York Palace Hotel in New York City on September 11-13, 2023.

uniQure N.V. announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for AMT-260, the Company’s gene therapy candidate for refractory mesial temporal lobe epilepsy.

Axsome Therapeutics, Inc., a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in three upcoming investor conferences in September.

ValGenesis, Inc. and Arizona Automation & Technologies have partnered to extend a suite of ValGenesis products across the life sciences sector in India, Bangladesh, and United Arab Emirates.

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, Chief Executive Officer of AIM, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY and virtually.

Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announces its management will participate in the following upcoming investor conferences in September.

LabGenomics USA, a subsidiary of LabGenomics Co., Ltd., announced its acquisition of QDx Pathology, a leader in molecular and diagnostic pathology.